Everything below concerns sirtuins. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
NAD+ is a dinucleotide composed of nicotinamide, ribose, and adenine linked by phosphate groups. Its full name is nicotinamide adenine dinucleotide, with "+" denoting the oxidized form. The molecule acts as a coenzyme in redox reactions, cycling between NAD+ and NADH. In cells, it participates in electron transfer during glycolysis, the citric acid cycle, and oxidative phosphorylation. It is distinct from NADP+, which carries an additional phosphate group and supports different biosynthetic reactions.
Beyond redox chemistry, NAD+ serves as a substrate for enzymes that transfer ADP-ribose or remove acetyl groups. Sirtuins, PARPs, and CD38-family enzymes consume NAD+ and produce nicotinamide and ADP-ribose-related products. These reactions link NAD+ availability to DNA repair, chromatin modification, and cellular signaling. Because the molecule is central to energy metabolism and regulation, changes in its concentration are studied in aging, immunity, and metabolic research. The balance between synthesis and consumption varies by tissue, developmental stage, and physiological state.
Stability of NAD+ depends on form, temperature, pH, and water content. The solid is generally more stable than solutions, and it should be kept dry and cold. In solution, hydrolysis can cleave the dinucleotide, especially under alkaline conditions or at elevated temperature. Light exposure may also contribute to degradation. Buffers, chelating agents, and sterile handling can reduce losses, but no single condition preserves all preparations indefinitely. Researchers often prepare working solutions shortly before use and verify activity or purity after storage.
Quality control for NAD+ relies on identity, purity, and functional tests. A certificate of analysis may report high-performance liquid chromatography purity, ultraviolet spectrum, water content, and residual solvents. Because NAD+ is hygroscopic, gravimetric values can shift as material absorbs water, so purity should be interpreted alongside storage history. Mass spectrometry confirms molecular identity, while enzymatic assays show whether the material supports dehydrogenase activity. Commercial material is available as the free acid and as salts, and the counterion affects molecular weight, solubility, and how concentrations are calculated.
Laboratory measurement of NAD+ usually begins with rapid sample quenching because the molecule can change form after collection. Enzymatic cycling assays amplify signal through coupled reactions and are suited to small samples. High-performance liquid chromatography with ultraviolet detection separates NAD+ from related nucleotides. Liquid chromatography-mass spectrometry offers higher specificity and can distinguish NAD+ from close analogs. Each method has trade-offs in sensitivity, throughput, and equipment needs, so reported values depend heavily on extraction and detection choices.
| Property | Value | Notes |
|---|---|---|
| Common name | Nicotinamide adenine dinucleotide (oxidized) | Often shortened to NAD+ |
| Chemical class | Dinucleotide | Contains nicotinamide and adenine moieties |
| Molecular formula | C21H27N7O14P2 | Free acid form; charge depends on pH |
| Molar mass | About 663.43 g/mol | Calculated for C21H27N7O14P2 |
| CAS number | 53-84-9 | Common identifier for beta-NAD+ |
Nicotinamide adenine dinucleotide, commonly abbreviated NAD+, is a coenzyme present in all living cells. The molecule consists of two nucleotides linked by phosphate groups, with adenine and a nicotinamide ring as its principal features. In its oxidized form, the nicotinamide ring can accept a hydride ion, becoming NADH. This reversible conversion places NAD+ at the center of many electron-transfer reactions. Its role as a redox carrier is well established across bacteria, plants, fungi, and animals.
Beyond redox chemistry, NAD+ acts as a substrate for several enzyme families. ADP-ribosyltransferases, sirtuins, and CD38 ectoenzymes cleave the molecule into nicotinamide and ADP-ribose or related products. These reactions connect NAD+ availability to processes such as DNA repair, chromatin modification, and calcium signaling. Because the coenzyme is used in both electron transfer and signaling, cells maintain separate pools in compartments including the cytosol, mitochondria, and nucleus. The relative sizes and regulation of those pools remain active areas of study.
Cells produce NAD+ through several biosynthetic routes. The salvage pathway recycles nicotinamide, while the Preiss-Handler pathway uses nicotinic acid, and a de novo route can start from tryptophan in some organisms. In mammals, the salvage pathway is generally considered the main source under ordinary conditions. Tissue concentrations vary widely by cell type and compartment, and measured declines with age have been reported in some studies. Whether such changes drive aging or mainly accompany it remains an open question.
NAD+ stands for nicotinamide adenine dinucleotide, the oxidized form of a coenzyme found in all living cells. The molecule consists of two nucleotides, adenine and nicotinamide ribose, joined through phosphate groups. Its chemical formula is C21H27N7O14P2, and the free acid has a molar mass near 663.43 grams per mole. In redox reactions, NAD+ accepts a hydride ion and becomes NADH. The pair NAD+ and NADH participates in hundreds of metabolic reactions, including steps in glycolysis, the citric acid cycle, and oxidative phosphorylation.
In cells, NAD+ functions primarily as an electron carrier. Dehydrogenase enzymes in glycolysis and the citric acid cycle transfer hydride from substrates to NAD+, producing NADH. NADH then delivers electrons to the mitochondrial respiratory chain, supporting ATP synthesis. In fermentation, NADH is reoxidized to NAD+ so that glycolysis can continue. The balance between NAD+ and NADH helps set metabolic flux. Beyond redox, NAD+ serves as a substrate for enzymes that cleave it, including sirtuins, poly(ADP-ribose) polymerases, and CD38. These reactions consume NAD+ and release nicotinamide and ADP-ribose products.
Biosynthesis occurs through salvage, Preiss-Handler, and de novo pathways. In mammals, the salvage pathway from nicotinamide predominates, and NAMPT is often described as rate-limiting. Nicotinamide riboside and nicotinic acid enter related routes that converge on NAD+ production. Tissue NAD+ concentrations vary widely and are maintained by a balance of synthesis and consumption. Some studies report age-related declines in certain tissues, but whether these changes cause disease or can be reversed to improve human health remains an open question.
The stability of NAD+ depends on pH, temperature, light exposure, and the presence of degradative enzymes. Aqueous solutions are generally more stable under mildly acidic to neutral conditions and degrade faster under alkaline conditions or prolonged heat. The solid is hygroscopic and should be stored desiccated, often frozen, and protected from repeated freeze-thaw cycles. In laboratory handling, aliquots reduce repeated temperature changes, and chelating agents may limit metal-catalyzed hydrolysis in some buffers. These practices matter because even small amounts of NADH or hydrolysis products can interfere with quantitative assays.
Quality control for NAD+ materials typically combines identity, purity, and water content checks. Identity may be confirmed by ultraviolet spectrum, retention time in chromatography, or mass accuracy, while purity is assessed by HPLC peak area or quantitative nuclear magnetic resonance. Residual water and solvents can affect molar calculations and enzyme assays, so Karl Fischer titration or thermogravimetric analysis may be used. Commercial materials vary in grade and counterion form, and published methods should specify the exact salt or hydrate when reporting concentrations. Regulatory status depends on intended use, with research reagents, dietary ingredients, and clinical products treated under different frameworks.
Measuring NAD+ in biological samples requires rapid processing because the compound can degrade or interconvert after collection. Common approaches include enzymatic cycling assays, high-performance liquid chromatography, and mass spectrometry. Each method has different sensitivity, specificity, and susceptibility to interference from related nucleotides. Sample type matters: cultured cells, animal tissues, and human blood present distinct challenges. Reported values can vary widely across laboratories because of differences in extraction, normalization, and analytical platform. Standardization remains an open issue in the field.
NAD+ is relatively unstable in aqueous solution, especially at neutral or alkaline pH and at elevated temperatures. It is typically stored dry, protected from light and moisture, and kept cold or frozen for long-term use. Solutions are often prepared fresh or buffered to mildly acidic pH to slow hydrolysis. Repeated freeze-thaw cycles can reduce integrity. Laboratories may verify concentration using ultraviolet absorbance at 259 nm or by enzymatic assay. These handling practices are general laboratory conventions rather than universal rules.
Research on NAD+ often examines changes with age, diet, exercise, and disease states, but causal relationships are difficult to establish. Some studies measure NAD+ levels, while others assess enzyme activity or downstream markers. In the literature, terms such as "NAD+ decline" and "NAD+ boosting" appear in both scientific and commercial contexts, sometimes without precise definitions. Whether changes in measured NAD+ directly produce health effects remains an open question. Results from cells, animals, and humans cannot be assumed to translate directly.
Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma, postpartum bleeding, surgery, tooth removal, nosebleeds, and heavy menstruation. It is also used for hereditary angioedema. It is taken either by mouth, injection into a vein, or by intramuscular injection. Tranexamic acid is a synthetic analog of the amino acid lysine. It serves as an antifibrinolytic by reversibly binding four to five lysine receptor sites on plasminogen. This decreases the conversion of plasminogen to plasmin, preventing fibrin degradation and preserving the framework of fibrin's matrix structure. Tranexamic acid has roughly eight times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid. Tranexamic acid also directly inhibits the activity of plasmin with weak potency (IC50 = 87 mM), and it can block the active-site of urokinase plasminogen activator (uPA) with high specificity (Ki = 2 mM), one of the highest among all the serine proteases. Side effects are rare; they include changes in color vision, seizures, blood clots, and allergic reactions. Tranexamic acid appears to be safe for use during pregnancy and breastfeeding. Tranexamic acid was first made in 1962 by Japanese researchers Shosuke and Utako Okamoto. It is on the World Health Organization's List of Essential Medicines. Tranexamic acid is available as a generic drug.
DT56a has been described in scientific literature as a selective estrogen receptor modulator (SERM)-like compound. Experimental studies have suggested that DT56a may exert agonistic effects on estrogen receptors in bone and brain tissues, while demonstrating limited activity in uterine and breast tissues. Several studies have investigated DT56a in relation to menopausal symptoms and bone health. In vitro studies have also reported stimulation of osteoblast activity in cultured human bone cells. Published studies have additionally suggested that DT56a does not significantly affect circulating hormone levels or blood coagulation parameters. Selective estrogen receptor modulator
The phosphatases in the PHLPP family, PHLPP1 and PHLPP2 have been shown to directly dephosphorylate, and therefore inactivate, distinct Akt isoforms, at one of the two critical phosphorylation sites required for activation: Serine473. PHLPP2 dephosphorylates AKT1 and AKT3, whereas PHLPP1 is specific for AKT2 and AKT3. Lack of PHLPP appears to have effects on growth factor-induced Akt phosphorylation. When both PHLPP1 and PHLPP2 are knocked down using siRNA and cells are stimulated using epidermal growth factor, peak Akt phosphorylation at both Serine473 and Threonine308 (the other site required for full Akt activation) is increased dramatically.
The fissile properties of uranium-233 were established at the University of California, Berkeley during 1941 and early 1942 by Glenn T. Seaborg, John W. Gofman and Raymond W. Stoughton, who showed that the isotope undergoes fission with slow neutrons and was therefore a potential nuclear fuel. Their report was mailed to the Uranium Committee in Washington on 14 April 1942, but wartime secrecy kept the work from open publication until 1947, when an abridged version appeared in Physical Review. In 1946, the public first became informed of uranium-233 bred from thorium as "a third available source of nuclear energy and atom bombs" (in addition to uranium-235 and plutonium-239), following a United Nations report and a speech by Glenn T. Seaborg. The United States produced, over the course of the Cold War, approximately 2 metric tons of uranium-233, in varying levels of chemical and isotopic purity. These were produced at the Hanford Site and Savannah River Site in reactors that were designed for the production of plutonium-239.
Sources: en.wikipedia.org
The University of Galway (Irish: Ollscoil na Gaillimhe) is a public research university located in the city of Galway, Ireland. It was founded in 1845 as Queen's College, Galway. It was known as "University College, Galway" from 1908 to 1997 and as "National University of Ireland, Galway" (NUI Galway) from 1997 to 2022. In September 2022, the university changed its name to "University of Galway". It is also a member of the Coimbra Group, a network of 42 long-established European universities.
== Scientific application == Clinical studies have investigated glutamine supplementation for supporting gut barrier function. Several randomized controlled trials and meta-analyses report that oral or enteral glutamine can reduce markers of intestinal permeability in acute or short-term settings, such as following intense exercise or during critical illness; however, results across chronic inflammatory conditions are inconsistent. Glutamine has also been studied for the prevention and management of chemotherapy- or radiation-induced oral and gastrointestinal mucositis. Multiple randomized trials and meta-analyses suggest that glutamine supplementation may reduce the incidence or severity of high-grade oral mucositis, although findings are heterogeneous and not all studies demonstrate benefit. In chronic inflammatory bowel diseases, including Crohn's disease, systematic reviews (including Cochrane reviews) have concluded that current randomized evidence is insufficient to support glutamine supplementation for inducing remission or modifying disease progression, and further well-powered clinical trials are required. While commercial and lay sources describe plausible mechanisms by which glutamine may support intestinal barrier function, such claims should be interpreted in the context of available clinical evidence.
The following year, Pauling published what he regarded as his most important paper, in which he first laid out the concept of hybridization of atomic orbitals and analyzed the tetravalency of the carbon atom. At Caltech, Pauling struck up a close friendship with theoretical physicist Robert Oppenheimer at the University of California, Berkeley, who spent part of his research and teaching schedule as a visitor at Caltech each year. Pauling was also affiliated with Berkeley, serving as a visiting lecturer in physics and chemistry from 1929 to 1934. Oppenheimer even gave Pauling a stunning personal collection of minerals. The two men planned to mount a joint attack on the nature of the chemical bond: apparently Oppenheimer would supply the mathematics and Pauling would interpret the results. Their relationship soured when Oppenheimer tried to pursue Pauling's wife, Ava Helen. When Pauling was at work, Oppenheimer came to their home and blurted out an invitation to Ava Helen to join him on a tryst in Mexico. She flatly refused, and reported the incident to Pauling. He immediately cut off his relationship with Oppenheimer. In the summer of 1930, Pauling made another European trip, during which he learned about gas-phase electron diffraction from Herman Francis Mark. After returning, he built an electron diffraction instrument at Caltech with a student of his, Lawrence Olin Brockway, and used it to study the molecular structure of a large number of chemical substances. Pauling introduced the concept of electronegativity in 1932.
Sources: en.wikipedia.org
The plus sign indicates the oxidized form of nicotinamide adenine dinucleotide, which can accept electrons. When it accepts electrons, it becomes NADH. The two forms together support redox reactions in cells.
No. NAD+ is the oxidized form and NADH is the reduced form. They differ by two electrons and a proton equivalent, and cells interconvert them during metabolism.
Yes. NAD+ is present in all living cells and is required for fundamental metabolic reactions. Its concentration varies by tissue, compartment, and time.
Common methods include enzymatic cycling assays, HPLC with UV detection, and LC-MS. The choice depends on sample size, specificity needs, and available equipment. Rapid quenching before analysis is important because NAD+ and NADH can interconvert.